Rocket Pharma officer reports 52,576 RSUs holding

Rocket Pharmaceuticals, Inc. executive Joseph Manhede, the Principal Accounting Officer, filed an initial ownership report showing his equity position in the company.

Rhea-AI Filing Summary

Rocket Pharmaceuticals, Inc. executive Joseph Manhede, the Principal Accounting Officer, filed an initial ownership report showing his equity position in the company. The filing reflects 52,576 shares of Common Stock held directly, represented by restricted stock units that convert to common shares on a one-for-one basis.

These RSUs were granted on May 4, 2026. One-third of the units will vest on May 4, 2027, with the remaining units vesting in equal quarterly installments over the following two years. The filing does not report any open-market purchases or sales, only the existing equity award and its vesting schedule.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Manhede Joseph

Role Principal Accounting Officer

Type	Security	Shares	Price	Value
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 52,576 shares (Direct)

Footnotes (1)

1. F1. Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis that were granted to the Reporting Person on May 4, 2026. One-third (1/3) of such RSUs will become fully vested on May 4, 2027, with the remaining shares vesting in equal quarterly installments over the following two years.

Key Figures

Common Stock equivalent: 52,576 shares Initial vesting portion: One-third of RSUs Remaining vesting period: Two years +1 more

4 metrics

Common Stock equivalent 52,576 shares Beneficial ownership following RSU grant

Initial vesting portion One-third of RSUs Vests on May 4, 2027

Remaining vesting period Two years Remaining RSUs vest in equal quarterly installments

Open-market transactions 0 No buy or sell transactions reported in Form 3

Key Terms

restricted stock units ("RSUs"), Common Stock, Principal Accounting Officer

3 terms

restricted stock units ("RSUs") financial

"Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Common Stock financial

"Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Principal Accounting Officer financial

"officer_title": "Principal Accounting Officer""

The Principal Accounting Officer is the person responsible for making sure a company's financial records are accurate and follow the rules. They play a key role in preparing financial reports that show how well the company is doing. This helps investors, managers, and regulators trust the company's financial information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Rocket Pharmaceuticals (RCKT) executive Joseph Manhede report on this Form 3?

Joseph Manhede reported his initial ownership of Rocket Pharmaceuticals equity. The filing shows he directly holds restricted stock units that convert into 52,576 shares of Common Stock, documenting his starting position as Principal Accounting Officer without reporting any open-market transactions.

How many Rocket Pharmaceuticals (RCKT) shares does Joseph Manhede beneficially own?

The Form 3 shows beneficial ownership of 52,576 shares of Rocket Pharmaceuticals Common Stock. These are represented by restricted stock units that convert to common shares on a one-for-one basis according to the vesting schedule described in the filing’s footnote.

What are the terms of Joseph Manhede’s RSU grant at Rocket Pharmaceuticals (RCKT)?

The RSUs were granted on May 4, 2026 and convert one-for-one into Common Stock. One-third of the RSUs will vest on May 4, 2027, with the remaining units vesting in equal quarterly installments over the subsequent two years.

Does this Rocket Pharmaceuticals (RCKT) Form 3 show any stock purchases or sales?

The Form 3 does not report any stock purchases or sales by Joseph Manhede. It only discloses his initial ownership position through restricted stock units and their vesting schedule, rather than recording open-market buying or selling activity.

What role does Joseph Manhede hold at Rocket Pharmaceuticals (RCKT)?

Joseph Manhede is identified as the Principal Accounting Officer of Rocket Pharmaceuticals. His Form 3 filing establishes his initial beneficial ownership of restricted stock units that convert into 52,576 shares of Common Stock, aligning his compensation with shareholder interests.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/08/2026 - 07:05 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Manhede Joseph

(Last) (First) (Middle)

C/O ROCKET PHARMACEUTICALS, INC.

9 CEDARBROOK DRIVE

(Street)

CRANBURY NEW JERSEY 08512

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/08/2026

3. Issuer Name and Ticker or Trading Symbol
ROCKET PHARMACEUTICALS, INC. [ RCKT ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock(1)	52,576	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis that were granted to the Reporting Person on May 4, 2026. One-third (1/3) of such RSUs will become fully vested on May 4, 2027, with the remaining shares vesting in equal quarterly installments over the following two years.

Remarks:

Exhibit 24: Power of Attorney

	/s/ Martin Wilson, as attorney-in-fact for Joseph Manhede	07/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)